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Dual Use of Bladder Anticholinergics and Cholinesterase
Inhibitors: Long-Term Functional and Cognitive Outcomes
Kaycee M. Sink, MD, MAS, Joseph Thomas, III, PhD,wz Huiping Xu, PhD,§ Bruce Craig, PhD,§
Steven Kritchevsky, PhD, and Laura P. Sands, PhDz k
OBJECTIVES: To determine the cognitive and functional
consequences of dual use of cholinesterase inhibitors (ChIs)
and the bladder anticholinergics oxybutynin or tolterodine.
DESIGN: Prospective cohort study.
SETTING: Nursing homes (NHs) in the state of Indiana.
PARTICIPANTS: Three thousand five hundred thirty-six
Medicaid-eligible NH residents aged 65 and older taking a
ChI between January 1, 2003, and December 31, 2004.
Residents were excluded if they were taking an anti-
cholinergic other than oxybutynin or tolterodine.
MEASUREMENTS: Indiana Medicaid claims data were
merged with data from the Minimum Data Set (MDS). Re-
peated-measures analyses were performed to assess the
effects of dual therapy on change in cognitive function
measured using the MDS Cognition Scale (MDS-COGS;
scored 0–10) and change in activity of daily living (ADL)
function using the seven ADL items in the MDS (scored 0–
28). Potential covariates included age, sex, race, number of
medications, and Charlson Comorbidity Index score.
RESULTS: Three hundred seventy-six (10.6%) residents
were prescribed oxybutynin or tolterodine concomitantly
with a ChI. In residents in the top quartile of ADL function,
ADL function declined an average of 1.08 points per quar-
ter when not taking bladder anticholinergics (ChI alone),
compared with 1.62 points per quarter when taking dual
therapy, a 50% greater rate in quarterly decline in ADL
function (P5.01). There was no excess decline attributable
to dual therapy in MDS-COGS scores or in ADL function
for residents who started out with lower functioning.
CONCLUSION: In higher-functioning NH residents, dual
use of ChIs and bladder anticholinergics may result in
greater rates of functional decline than use of ChIs alone.
The MDS-COGS may not be sensitive enough to detect
differences in cognition due to dual use. J Am Geriatr Soc
56:847–853, 2008.
Key words: dementia; incontinence; pharmacotherapy;
anticholinergics; cholinesterase inhibitors
Older adults, particularly those in nursing homes(NHs), are likely to have multiple medical conditions
requiring complex medical management that can lead to
therapeutic dilemmas. For example, two of the most com-
mon medical conditions in NH residents are dementia and
urinary incontinence (UI), and they often coexist.1,2 Cho-
linesterase inhibitors (ChIs) are commonly prescribed to
persons with dementia to reduce rates of cognitive and
functional decline by increasing acetylcholine levels at brain
synapses, but therapeutic agents that are used to treat con-
ditions that frequently coexist with dementia, such as UI,
may reduce potential beneficial effects of ChIs. The agents
typically used to treat UI have anticholinergic properties,
acting on muscarinic receptors to decrease acetylcholine.
Thus, anticholinergics and ChIs are in pharmacological
opposition, and the simultaneous pharmacological treat-
ment of dementia and UI could lead to reduced effectiveness
of one or both drugs.
Although dual use of ChI and anticholinergics occurs
for as many as one-third of persons with dementia,3,4 the
extent to which dual use of these drugs is associated
with excess cognitive and functional deterioration has not
been determined. Prior studies have demonstrated that use
of anticholinergics, including bladder anticholinergics, is
associated with cognitive impairment in persons with de-
mentia,5–7 but data documenting outcomes in patients
concomitantly taking ChIs and anticholinergics are limited
to case reports and small observational studies.8–10 In ad-
dition, prior studies have typically been conducted over
short intervals and have not determined whether long-term
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use of anticholinergics is associated with greater rates of
cognitive and functional decline over time.11
The goals of this study were, therefore, to examine
changes in function in activities of daily living (ADLs) and
cognition over time in NH residents taking ChIs while re-
ceiving concomitant therapy with a bladder anticholinergic
(dual use) and in those taking ChIs without a bladder anti-
cholinergic. It was hypothesized that the bladder anti-
cholinergics oxybutynin and tolterodine would decrease the
efficacy of ChIs with respect to cognitive and functional
outcomes. Loss of functioning in persons with dementia is
costly to consumers and the government.12 Information
is needed regarding prescribing practices that may acceler-
ate rates of cognitive and functional decline in persons with
dementia.
METHODS
Subjects and Study Design
Medicaid eligibility and claims data from the Indiana Fam-
ily and Social Services Administration were merged with
Minimum Data Set (MDS) data from the Social Services
Administration to create a data set with detailed drug pre-
scription claims data (Medicaid) and clinical data (MDS).
Identifying information was replaced with unique identifi-
ers to protect the privacy of patients’ health information.
The institutional review board at Purdue University ap-
proved the study.
Subjects were included if, between January 1, 2003,
and December 31, 2004, they were eligible for Indiana
Medicaid benefits, were aged 65 and older, had at least
two consecutive prescriptions for a ChI (donepezil, gal-
antamine, rivastigmine, or tacrine), and had at least two
consecutive NH MDS assessments while continuously
taking a ChI. Subjects were excluded if they were taking
an anticholinergic other than oxybutynin or tolterodine
during the period in which they contributed data to
the analyses.3,4,13 Derivation of the cohort of 3,536
residents who met the inclusion criteria is diagrammed in
Figure 1.
The starting date of each subject’s study interval was
defined as the date of the first nonadmission MDS assess-
ment after the resident’s first prescription for a ChI between
January 1, 2003, and December 31, 2004. The admission
assessment was not included, because functioning at the
admission assessment may be temporarily depressed be-
cause of the acute illness or event that precipitated the NH
placement. The end date of the study interval was the last
MDS assessment before discontinuation of the ChI, initi-
ation of an anticholinergic other than the bladder anti-
cholinergics oxybutynin or tolterodine, or December 31,
2004, whichever came first. Only assessments that occurred
while the subject was continuously taking a ChI were in-
cluded in the analyses. Based on the dates of claims for
prescriptions and the number of tablets dispensed, the
assumption was made that the ChI use was continuous if
a refill of the ChI was obtained within 60 days after ex-
hausting the supply from the previous prescription.14 If
subjects were continuously taking a ChI between January 1,
2003, and December 31, 2004, they could contribute as
many as 2 years of assessment data to the analyses.
Measures
Predictors
The two predictor variables were the number of days of
continuous ChI use without dual use of a bladder anti-
cholinergic and the number of days of continuous ChI
use with dual use of oxybutynin or tolterodine. Because
change in function between adjacent MDS assessments
was modeled, the number of days the subject was contin-
uously taking a ChI was computed as the number of days
between two consecutive MDS assessments during which
the subject was continuously taking a ChI. Similarly, the
number of bladder anticholinergic days was computed as
the number of days between consecutive MDS assessments
in which the subject was simultaneously taking oxybutynin
or tolterodine and a ChI. When computing the number of
days of bladder anticholinergic use, it was assumed that
the subject was continuously taking the drug between the
first day the prescription was filled until the prescription
was exhausted.
The coefficients for the predictor variables represent
the daily changes in the outcome when taking or not taking
dual therapy. The difference between the coefficients rep-
resents the additional change in the outcome associated
with dual therapy. Because the MDS assessments were gen-
erally made quarterly, the coefficients were multiplied by
90 to present the amount of change per quarter rather than
per day.
Residing in a NH and aged 65 and older in 2003/04 
n = 43,739 
No prescriptions of anticholinergics other than 
oxybutynin or tolterodine within 30 days of the dementia 
drug prescription 
n = 6,059 
ChI only 
n = 3,141
ChI + bladder anticholinergic*†
n = 395 
Tolterodine
n = 231 
Oxybutynin  
n = 196 
Having at least two consecutive dementia drug (ChI) 
prescriptions while in the NH 
n = 10,626 
Having at least two Minimum Data Sets assessments 
(not including admission) and residing in the NH
continuously between the two assessments 
n = 3,536 
Figure 1. Sample source. Thirteen people were taking ox-
ybutynin and tolterodine at separate times. wNineteen people
taking oxybutynin and tolterodine simultaneously were exclud-
ed from analyses assessing change in cognition and functioning
associated with specific bladder drug use. NH5 nursing home;
ChI5 cholinesterase inhibitor.
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Outcomes
This study had two primary outcomes. First, level of func-
tioning in ADLs was determined using the MDS ADL-Long
Form,15 which included assessments of dressing, personal
hygiene, toileting, transferring, bed mobility, eating, and
locomotion on the unit. Each ADL item was scored from 0
to 4, with 0 reflecting complete independence and 4 re-
flecting complete dependence. The scores were summed to
create a scale score that ranged from 0 to 28, with higher
scores indicating greater dependence. The ADL-Long Form
has been shown to be reliable (a50.94) and sensitive to
change over time.15 ADL assessments occurred quarterly
and when there was significant change in the patient’s
health status.
The second primary outcome was change in cognitive
functioning as measured with the MDS-Cognition Scale
(MDS-COGS).16 The MDS-COGS score was generated
from seven items that assessed short- and long-term mem-
ory, orientation, communication, and dressing. Those items
were scored 0 to indicate no disability in that area of func-
tioning or 1 to indicate disability in that area of functioning.
The scale score also included a 3-point item that reflected
the subject’s ability to make decisions, with 0 reflecting the
ability to make decisions, 1 reflecting mild disability, and 2
reflecting inability to make decisions. Scores were summed
and ranged from 0 to 10, with higher scores indicating
worse cognition. The instrument has good internal consis-
tency (a50.85)17 and has been validated against the Mini-
Mental State Examination (MMSE).16,17 The MDS-COGS
was also obtained quarterly and whenever there was sig-
nificant change in the patient’s health status.
Covariates
Variables that might explain the relationship between dual
use of ChIs and anticholinergics and cognitive or functional
decline were considered. They were sex, age (65–74, 75–79,
80–84, 85–89, and 90), race (white or other), and the
number of medications used in the 7 days before the first
assessment. These variables were obtained from the MDS
data. A modified Charlson Comorbidity Index18 was cal-
culated based on claims data from the 12 months before the
start of each subject’s study interval. This modified Charl-
son index was computed using an algorithm validated with
administrative claims data.19 Scores were categorized as 0,
1, or 2 or greater, with higher scores indicating greater
number and severity of comorbidities.
Statistical Analysis
To assess the effects of dual therapy on change in ADL
function over time, repeated-measures analyses were per-
formed. Piecewise linear regression was used to model the
change between each adjacent pair of observations of ADL
functioning. Predictors were the number of days taking and
not taking dual therapy between the adjacent observations.
To allow rates of change to vary for different levels of
functioning at the beginning of the interval, the interactions
between time taking dual therapy and ADL category at the
start of each interval and between time not taking dual
therapy and ADL category at the start of the interval were
included. ADL category was categorized according to quar-
tiles (0–5 was considered to reflect little or no dependence,
6–12 moderate dependence, 13–19 severe dependence, and
20–28 complete or nearly complete dependence). Results
are reported for the TOEP(2) correlation structure, because
it produced the best-fitting model, although results did not
vary significantly when other correlation structures were
employed. Adjusted estimates of change in functioning
were computed by including covariates in the repeated-
measures model. Although age, race, sex, number of med-
ications, and Charlson comorbidity scores were initially
included as potential covariates, only age was retained in
the model, because it was the only covariate that signifi-
cantly contributed to the prediction of change in ADL scale
scores.
A similar model was run in which the dependent vari-
able was the MDS-COGS score. The interaction was mod-
eled as the time taking and not taking dual therapy, with a
categorical variable that described the subjects’ MDS-
COGS level of functioning at the start of the interval. The
MDS-COGS categories were defined as: intact (0–1), mod-
erate impairment (2–4), severe impairment (5–8), and very
severe impairment (9–10).16 Residents with scores of 10
were not excluded to allow for the possibility that they
might improve. Adjusted estimates of change in MDS-
COGS score were computed by including covariates in the
repeated-measures model. Age, race, sex, number of med-
ications, and Charlson comorbidity score were included as
potential covariates in the model but were not retained,
because they did not significantly contribute to the predic-
tion of MDS-COGS change.
Because tolterodine is less lipophilic and therefore
thought to be less likely to cross the blood–brain barrier,20
additional analyses were conducted to compare rates of
decline in ADL function and cognition for the two bladder
anticholinergics by differentiating time taking oxybutynin
and time taking tolterodine. The statistical model was sim-
ilar to those described above except that three predictor
variables were included: number of days not taking dual
therapy, number of days taking oxybutynin, and number of
days taking tolterodine. The difference between the coeffi-
cients associated with the days not taking dual therapy and
taking oxybutynin represents the additional change in func-
tioning associated with dual use of a ChI and oxybutynin.
Similarly, the difference between the coefficients associated
with the days not taking dual therapy and taking toltero-
dine represents the additional change in functioning asso-
ciated with dual use of a ChI and tolterodine. Age, race, sex,
number of medications, and Charlson comorbidity score
were included as potential covariates in the model but were
not retained, because they did not significantly contribute to
the prediction of ADL or cognitive change. As shown in
Figure 1, 13 residents had exposure to oxybutynin and to-
lterodine at separate times during the study. For these sec-
ondary analyses, the time they were taking oxybutynin
contributed to the oxybutynin results, and the time they
were taking tolterodine contributed to the tolterodine re-
sults. Nineteen residents were taking both drugs simulta-
neously. Because it was not possible to separate the effect of
one drug from the other, these 19 residents were excluded
from this drug-specific secondary analysis.
Finally, because side effects, including central nervous
system side effects, are reported to be more common with
immediate-release preparations,21,22 additional analyses
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were performed to determine whether there was a differ-
ence in rates of decline in ADL function and cognition for
immediate- versus extended-release formulations. In similar
models to those described above, the predictors were time
not taking bladder anticholinergic, time taking and imme-
diate-release formulation of oxybutynin or tolterodine,
and time taking and extended-release formulation of ox-
ybutynin or tolterodine.
Analyses were performed using SAS statistical soft-
ware, version 9.1 (SAS Institute, Inc., Cary, NC).
RESULTS
Characteristics of the 3,536 residents enrolled in this study
and followed for a median of 183 days are presented in
Table 1. Briefly, 44% were among the oldest old (aged
85), 75% were women, and 90% were white. More than
half of the sample had severe or very severe cognitive im-
pairment, and 47% had severe or complete dependence in
ADL functioning. Forty-six percent were incontinent at
least once daily. Incontinence is reported in the MDS on a
scale ranging from 0 (continent) to 4 (multiple daily epi-
sodes of urinary incontinence). Residents in the highest two
categories of the variable (incontinent daily (but with some
control) and multiple daily episodes of incontinence) were
considered to be incontinent at least daily. All residents
were taking a ChI; the most common was donepezil
(70.5%), followed by rivastigmine (19.9%), galantamine
(16.5%), and tacrine (0.1%). (Percentages sum to4100%
because some residents changed cholinesterase inhibitors
during the study period.) The mean number of total pre-
scription medications  standard deviation was 9.6  4.1.
Of the 3,536 residents included in this study, 376
(10.6%) were prescribed bladder anticholinergics with a
ChI (oxybutynin (n5164), tolterodine (n5199), both at
separate times (n513), or both simultaneously (n519))
(Figure 1). Of the residents taking bladder anticholinergics,
197 were taking immediate-release formulations, and 268
were taking extended-release formulations over the course
of the study. Some residents used both at different times. Of
residents who took a bladder anticholinergic during the
study, 75.5% continued using them for more than half of
their study interval. The median (25th–75th percentile) du-
ration of dual use was 141 (77–262) days.
ADL Function
In unadjusted analyses, residents in the top quartile of ADL
function who were not taking bladder anticholinergics
(taking ChIs alone) declined in ADL function by an average
of 1.08 points per quarter. Dual therapy with bladder anti-
cholinergics was associated with an additional worsening
of 0.54 ADL points per quarter (P5.01). For residents
who started out with lower functioning, dual use was not
associated with additional worsening in ADL scores.
Results did not vary significantly after accounting for au-
tocorrelation and adjusting for age. Adjusted results are
presented in Table 2.
To compare rates of change in function specific to type
of bladder anticholinergic, subjects taking oxybutynin were
compared with those taking no bladder anticholinergic.
Similarly, subjects taking tolterodine were compared with
those not taking a bladder anticholinergic. Regardless of
level of functioning at the beginning of the interval, rates of















Activity of daily living score, (range 0–28)
Mean  SD 12.2  8.1
None to little dependence (0–5), % 27.6
Moderate dependence (6–12), % 25.2
Severe dependence (13–19), % 25.3
Complete or nearly complete dependence (20–28), % 21.9
Minimum Data Set Cognitive Subscale score (range 0–10), %
Intact (0–1) 10.0
Moderate impairment (2–4) 37.8
Severe impairment (5–8) 45.7
Very severe impairment (9–10) 6.5
Number of medications, mean  SD 9.6  4.1
Bladder incontinence (at least once daily), % 45.9




Table 2. Difference in Change in Function While Taking





Activity of daily living scale score (range 0–28)
None to little dependence  0.53 .02
Moderate dependence 0.27 .21
Severe dependence 0.14 .52
Complete or nearly complete dependence  0.03 .92
Minimum Data Set Cognitive Subscale (range 0–10)w
Intact 0.08 .36
Moderate impairment 0.05 .50
Severe impairment 0.05 .47
Very severe impairment 0.25 .86
Note: Negative estimates refer to greater decline in functioning while taking
versus not taking a bladder anticholinergic.
Analyses were adjusted for age. Race, sex, number of medications, and
Charlson Score were not independently associated with the rate of decline.
wAge, race, sex, number of medications, and Charlson score were not inde-
pendently associated with the rate of decline.
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decline in ADL function for those taking oxybutynin or
tolterodine were not statistically different from rates of de-
cline for those not taking a bladder anticholinergic (Table
3). Nevertheless, for the highest functioning, the magnitude
of the difference for oxybutynin was the same as for the
combined analysis (0.54 points/quarter), although this
trend was not statistically significant (P5.10). There were
no significant differences in rates of ADL decline for im-
mediate- and extended-release formulations.
Cognitive Function
Rates of worsening in MDS-COGS scores did not differ
significantly for residents taking a ChI, but not taking a
bladder anticholinergic, and those who received bladder
anticholinergics in addition to a ChI (Table 2). Similarly,
regardless of level of cognitive impairment at the beginning
of the interval, rates of decline in cognitive functioning did
not differ for those taking oxybutynin or tolterodine and
those not taking a bladder anticholinergic (Table 3). Res-
idents whose cognitive functioning was classified as very
severely impaired were not included in this analysis, be-
cause too few residents in the very severely impaired group
were taking each of the bladder anticholinergics. There
were no significant differences in rates of decline in MDS-
COGS scores when comparing immediate- and extended-
release formulations.
DISCUSSION
Even though dual use of anticholinergics and ChIs is com-
mon, prior studies have not documented the long-term det-
rimental effects of dual therapy on patients’ functioning.
This study revealed that, for NH residents with higher levels
of functioning, the rate of functional decline was 50% fast-
er when bladder anticholinergics were used in combination
with ChIs than when ChIs were used without anti-
cholinergics. To the authors’ knowledge, this is the first
study to provide objective evidence that simultaneous use of
bladder anticholinergics and a ChI is associated with excess
decline in patients’ functioning. Additional loss of func-
tioning inNHpatients reduces patients’ quality of life and is
costly to NHs. Although the findings from this study cannot
describe whether the therapeutic benefits of the bladder
anticholinergic outweigh the additional decline in func-
tioning associated with their use, it reveals that pharmaco-
logical management of dementia and UI poses a clinical
dilemma.
Prior studies have shown that anticholinergics are as-
sociated with cognitive decline11,23,24 and that persons with
dementia are especially sensitive to the cognitive side effects
of anticholinergics,5–7 but few studies have considered the
cognitive and functional consequences of concurrent use of
anticholinergics and ChI. To the authors’ knowledge, the
only published data on outcomes with the combination of
anticholinergics and a ChI have been in case reports8,9 and
one small longitudinal study.10 In that longitudinal study,
two groups of patients were studied for 2 years. One group
consisted of 16 patients who were taking one or more anti-
cholinergics in combination with donepezil. The other
group consisted of 53 patients who were taking donepezil
but not an anticholinergic. Those taking dual therapy de-
clined by 7 points on the MMSE over 2 years, compared
with a 3-point decline seen in those taking donepezil but no
anticholinergic. Unlike the above study that compared rates
of decline between two groups of patients with varying drug
treatments (and potentially different characteristics that led
to different treatment patterns), the current study assessed
whether patients experienced greater decline while taking
or not taking dual therapy.
It is likely that the oppositional pharmacological effects
of anticholinergics and ChI contribute to the accelerated
rates of decline in ADL function seen for subjects on dual
therapy. Oxybutynin and tolterodine block muscarinic re-
ceptors in the brain, resulting in lower acetylcholine levels,
whereas ChIs act to increase acetylcholine levels in brain
synapses by inhibiting the enzyme acetylcholinesterase,
which breaks down acetylcholine in the synaptic cleft. ChIs
have been shown in randomized, controlled trials to delay
onset of ADL disability.25 In addition, there is mounting
evidence that anticholinergics blocking muscarinic recep-
tors in the brain are associated with greater Alzheimer’s
neuropathology in animals26 and humans.27 Therefore, the





P-Value(Points per Quarter) (Points per Quarter)
Activity of daily living scale score (range 0–28)
No to little dependence  0.53 .10  0.38 .23
Moderate dependence 0.35 .24  0.13 .70
Severe dependence  0.18 .56 0.43 .16
Complete or nearly complete dependence 0.01 .99  0.17 .71
Minimum Data Set Cognitive Subscale (range 0–10)w
Intact  0.06 .60  0.23 .06
Moderate impairment 0.13 .06  0.10 .22
Severe impairment  0.02 .77 0.04 .60
Note: Negative estimates refer to greater decline in functioning while taking versus not taking the bladder anticholinergic.
Analyses were adjusted for age. Race, sex, number of medications, and Charlson score were not independently associated with the rate of decline.
wResidents in the very severe impairment category were excluded from this analysis’ because too few of them were taking each of the respective drugs. Age, race,
sex, number of medications, and Charlson score were not independently associated with the rate of decline.
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bladder anticholinergics could be accelerating the dement-
ing process. Although significantly worsening MDS-COGS
scores were not found with dual use, additional ADL de-
cline was found. Because cognitive decline is strongly
associated with subsequent loss of ADL function,28–30 it
is likely that the nonsignificant findings for the MDS-
COGS were because the MDS-COGS was created to
stage dementia severity rather than to quantify change in
neuropsychological functioning over time. Scores on the
MDS-COGS are based on reports by facility staff about the
residents’ ability to do things such as find their way back
to their room, make themselves understood and understand
others, and remember things after 5 minutes and in the
distant past. Although the possibility that there is no
effect of dual use of bladder anticholinergics and ChI on
cognition cannot be excluded, a more plausible explanation
is that the measure is not sensitive to detecting change in
specific areas of cognitive functioning such as memory or
concentration.
Although this study provides evidence to support the
hypothesis that dual therapy with ChIs and bladder anti-
cholinergics results in worse functional outcomes than
management with ChI alone, there are several additional
limitations to the study. First, given the observational na-
ture of the study, the reasons patients may take bladder
anticholinergic therapy could not be controlled for, which
may contribute to the reason patients are declining at a
faster rate while taking dual therapy. It was attempted to
limit potential confounding by indication through a study
design that used subjects as their own controls, comparing
rates of decline while taking and not taking bladder anti-
cholinergics. In addition, only bladder anticholinergics
were considered. Thus, subjects who were taking anti-
cholinergics for other indications (such as depression) that
may be associated with functional decline were excluded.
This study revealed a significant association between dual
therapy and ADL decline only for those with the highest
level of ADL functioning. These subjects were also the least
likely to have UI, which suggests that UI status, rather than
use of a bladder anticholinergic, is unlikely to explain
the findings. A randomized, controlled trial is needed to more
precisely determine the magnitude of excess ADL decline
that can be attributed to dual therapy. Second, the measures
used in this study were not sensitive for detecting change in
functioning for those at the lowest levels of functioning. It is
possible that the lack of significant findings for those at the
lowest levels of functioning was due to a floor effect in the
outcome measures. Future assessment of adverse effects of
dual therapy in persons with severe dementia must include
measures that are sensitive to changes in those with very
low levels of functioning. Third, cases of dementia were
identified using International Classification of Diseases,
Ninth Revision, codes rather than established clinical di-
agnostic criteria. This prevents determination of whether
the findings were similar for all types of dementia. Although
the Food and Drug Administration (FDA) has not approved
ChIs for non-Alzheimer’s dementias, they are prescribed for
vascular dementia and Lewy Body dementia,31,32 and
mechanistically, the pharmacological opposition between
ChIs and bladder anticholinergics occurs irrespective of
type of dementia. If ChIs were less effective in subjects
with non-Alzheimer’s dementia, inclusion of cases of non-
Alzheimer’s dementia might have attenuated the reported
effect of dual therapy. Fourth, the findings may not be gen-
eralizable to all bladder anticholinergics or doses. Although
there are newer bladder anticholinergics on the market that
are reported to be more selective for bladder muscarinic
receptors (e.g., darifenacin) or less likely to cross the blood–
brain barrier (e.g., trospium), oxybutynin and tolterodine
were examined, because the newer agents were not FDA
approved until late 2004, the end of the study period. Nev-
ertheless, oxybutynin and tolterodine continue to be the
most widely prescribed bladder anticholinergics. In addi-
tion, a recent review highlights that all bladder anti-
cholinergics should be considered to have the capacity to
cross the blood–brain barrier, especially in older adults,
because the blood–brain barrier becomes leaky with age
and comorbidities.33 Studies of the cognitive side effects of
the newer agents are needed, particularly in people with
dementia.
These results have significant public health implica-
tions. The additional decline of 0.5 points per quarter in this
study translates to 2 points per year on theMDS ADL scale.
A 2-point decline would represent a change from requiring
only limited assistance in an ADL to being completely de-
pendent in an ADL or from requiring only supervision in
any particular ADL to requiring extensive assistance. One
study estimates that, for every additional ADL dependency,
there is an increase of $1,958 (1998 dollars) in healthcare
costs per year.12 In addition, bladder anticholinergics and
ChIs are costly and only modestly effective.34–36 The com-
bined monthly consumer cost for a ChI and oxybutynin or
tolterodine is approximately $200. If using these medicines
together reduces the desired effect of the ChI or the incon-
tinence drug, then it is adding significant cost with reduced
benefit and potentially adding risk of harm.
Until now, the clinical dilemma for the pharmacolog-
ical management of dementia and UI has been largely the-
oretical. The findings reported in this study suggest that the
dual use of ChIs and bladder anticholinergics may lead to
worse functional outcomes, which is the opposite intention
of ChI therapy. Because the negative functional effect of
dual therapy was found only for NH residents with the
highest function, additional studies should be conducted in
a population of community-dwelling older adults with de-
mentia. In addition, studies using more-sensitive measures
of cognition are needed, as well as studies of newer, pre-
sumably more selective bladder anticholinergics. To truly
determine whether the risks of dual therapy to cognition
or function outweigh benefits for UI, changes in continence
status also need to be included as outcomes. Clinicians
should continue to implement nonpharmacological man-
agement strategies for incontinence before beginning
drug therapy,37 especially because the etiology of inconti-
nence in many patients with dementia is functional rather
than urge.38
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